ow-energy extracorporeal cardiac shock wave therapy in patients with severe ischemic heart disease

Not Applicable

• Conditions: Angina pectoris

• Registration Number: JPRN-UMIN000003003
• Lead Sponsor: Tohoku University

Brief Summary

CSWT markedly improved weekly nitroglycerin use and the symptoms. CSWT also significantly improved 6-min walking distance. Percent myocardium ischemia assessed by drug-induced stress MPI tended to be improved only in the treated segments.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-01-12
• Study Completion: 2016-10-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients whose target area cannot be observed with echocardiography. 2) Post-breast augmentation surgery with silicon pad. 3) Patients with prosthetic valve (mechanical valve) in the heart. 4) Q-wave myocardial infarction within 3 months. 5) Non-Q-wave myocardial infarction within 6 weeks. 6) Less than 1 month after the last revascularization (PCI or CABG). 7) Patients with cardiogenic shock or worsening heart failure (who require continuous infusion of cardiovascular agents such as inotropic agents or vasodilators). 8) Intracardiac thrombus. 9) Patients whose clinical status changed after the last coronary angiography. 10) Unstable diabetic retinopathy. 11) Patients who have malignancy or who have undergone surgery because of malignancy within the past five years.

Study & Design

• Study Type: Interventional
• Study Design: Not specified